May. 19, 2015
May 19, 2015. MabSpace Biosciences Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd have announced their collaborative contract to co-develop novel antibody therapeutics on two targets.
According to the agreement, MabSpace will be responsible for the discovery and selection of humanized lead antibodies, while Hengrui will hold exclusive global rights on the resulting therapeutic candidates for the nominated targets, and will further develop the selected candidate molecules.